spec sheet12 rows
LM22A-4 is a rationally designed small-molecule mimetic of the loop-II domain of BDNF that activates the TrkB neurotrophin receptor, discovered by in-silico screening in the Longo and Massa labs. It is a foundational research tool for the BDNF/TrkB arm of the neuroplasticity pathway, with broad neuroprotective, remyelinating, and cognition-rescuing activity across rodent models; offering a drug-like way to probe signaling normally driven by a large neurotrophin.
- Improves motor learning after traumatic brain injury (rodent)
- Neuroprotective for retinal ganglion cells (rodent)
- Promotes remyelination and rescues chemotherapy-related cognitive impairment (rodent)
- Activates TrkB/MAPK plasticity signaling in cell and animal models
- LM22A-4 was discovered by computationally screening a virtual library for small molecules mimicking the loop-II domain of BDNF ; a structure-guided attempt to replace a large neurotrophin with a drug-like molecule.
- It has never been tested in humans; every reported benefit comes from cell and rodent experiments.
- Some studies suggest part of its activity may come from indirectly transactivating Trk receptors rather than binding TrkB directly, so the 'selective TrkB agonist' label deserves nuance.
Mechanism
partial / -loop-domain mimetic: it engages TrkB to trigger MAPK/ERK survival and plasticity signaling, promoting neuronal survival and myelination. Its signaling kinetics differ from native BDNF, and evidence in oligodendroglia suggests part of its effect may arise from indirect Trk transactivation rather than direct receptor binding.
⚠️ That receptor-level account is contested, and it is the main thing to know about this compound. The founding work reported it as a loop-domain mimetic that activates [1]. Two independent groups have since failed to reproduce that activation. An industry drug-discovery consortium tested a panel of reported small-molecule agonists alongside a monoclonal antibody as a positive control, and this compound did not mimic [6]. A second group, using multiplex quantitative assays, reported that they could not observe , ERK or responses, and titled their paper a call to reevaluate the whole class [5]. A later review reached the same conclusion [7].
⚠️ The affinity figure that circulates is weaker than it sounds. The often-quoted 47 nanomolar is an IC50 upper bound from a competition assay, published as "or less" rather than as a fitted value, and it appears only in the original paper. There is no dissociation constant, no surface plasmon resonance, no isothermal titration and no saturation binding, and no independent laboratory has reproduced it by any binding method.
⚠️ The numbers also disagree with how the compound is actually used. Its stated survival potency is 200 to 500 picomolar, yet experiments use it at 500 nanomolar in cells and at far higher concentrations injected into brain ventricles. A gap of a thousandfold or more between a claimed potency and the working concentration usually means the potency figure is not describing the effect being produced.
What survives is worth stating fairly: downstream biological effects have been reproduced elsewhere, including increased oligodendrocyte populations during repair [3]. Something is happening. What is disputed is the explanation that it happens by binding .
receptor fingerprint
MAPK/ERK pathwayDownstream activation
Oligodendrocyte myelinationPromotion of myelin repair
receptorClaimed partial agonist; failed independent replication
Trk transactivation (indirect)Indirect receptor activation
Evidencehow good the literature is
Preclinical only, but reproduced across many independent rodent and cell models: improved motor learning after traumatic brain injury, retinal ganglion cell neuroprotection, promotion of remyelination, and rescue of chemotherapy (methotrexate)-related cognitive impairment. There is no clinical or human safety data.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
No human safety data exist; the safety profile is understood only from rodent studies. It should carry a clearly investigational, experimental designation and is not suitable for human use.
History
LM22A-4 was designed in the Longo and Massa laboratories by computationally screening a virtual compound library for small molecules mimicking a BDNF loop domain, then validated as a TrkB-activating tool compound. It has become a standard reagent for studying BDNF/TrkB biology.
Reputation
In academic neuroscience LM22A-4 is well known as a go-to small-molecule BDNF mimetic for interrogating TrkB signaling in disease models. It has no consumer following of note and remains entirely preclinical.
Subjective profileweighing the evidence above
A preclinical-only research compound with no human data of any kind. It is mechanistically central and widely used as a BDNF-mimetic probe, but some studies indicate it may act partly through indirect Trk transactivation rather than clean, direct TrkB binding; so the 'selective TrkB agonist' label deserves nuance and it must be treated as strictly experimental.
Resources
This entry is here for reference.
Research
- 2010first citedSmall molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in roden…
- 2021most recentDo Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Publis…
- 1.Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents.
- 2.Loss of Adaptive Myelination Contributes to Methotrexate Chemotherapy-Related Cognitive Impairment.
- 3.TrkB Agonist LM22A-4 Increases Oligodendroglial Populations During Myelin Repair in the Corpus Callosum.
- 4.A Small Molecule TrkB Neurotrophin Receptor Partial Agonist as Possible Treatment for Experimental Nonarteritic Anterior Ischemic Optic Neuropathy.
- 5.Multiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists
- 6.A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease
- 7.Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists.
7 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is LM22A-4 proven to enhance human cognition?
No. It has never been studied in humans. All reported benefits are from cell and rodent experiments.
Is it a clean, selective TrkB agonist?
Not entirely. It mimics part of the BDNF molecule and activates TrkB, but evidence suggests some effects may involve indirect Trk transactivation.
Can I take it?
No. There is no human dose, no safety data, and no consumer product; it is a laboratory research tool.
Limitations of the evidence
- Two independent groups, one an industry consortium with an antibody positive control, failed to reproduce TrkB activation
- The circulating 47 nM figure is an IC50 upper bound from a competition assay, not a measured binding constant
- No dissociation constant has ever been published, and no binding method has independently reproduced the original result
- Its stated picomolar potency is a thousandfold or more away from the concentrations it is actually used at
- No human exposure, no clinical trial and no pharmacokinetic data
Notes and cautions
- Unknown in humans (no clinical data)